Sutro Biopharma Inc (STRO) News

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...